Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trialYuankai Shi, Peng Liu, Xiuhua Sun et al.|The Lancet Haematology|2019Cited by 248
A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphomaYuankai Shi, Xin Zhang, Yongping Song et al.|Journal of Hematology & Oncology|2020Cited by 50